Filing Details

Accession Number:
0001725160-24-000127
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-05-31 18:27:15
Reporting Period:
2024-05-31
Accepted Time:
2024-05-31 18:27:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1725160 Zentalis Pharmaceuticals Inc. ZNTL () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1557832 Cam Gallagher C/O Zentalis Pharmaceuticals, Inc.
1359 Broadway, Suite 801
New York NY 10018
President, Interim Cfo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-05-31 9,597 $11.98 633,680 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.